# 

### Computational Challenges of Systems Biology

Anthony Finkelstein University College London CoMPLEX & Computer Science

*Work with* Jonathan Ashmore, David Bogle, James Hetherington, Linzhong Li, Ofer Margoninski, Peter Saffrey, Rob Seymour & Anne Warner





- New applications of computing rarely attract much attention from computer scientists unless they pose novel computational challenges, stretch the state-ofthe-art or open an unanticipated use of computing concepts.
- Bioinformatics is an example of an application that has attracted such attention ...











































#### Systems Engineering 101

Only when you understand the task that lies in front of you can you devise an appropriate strategy. A mistake now - in the planning stage - of systems biology will be immensely costly subsequently





The models are flat and there is no indication or understanding of the level at which these models should be built. There is no 'information hiding' Models are presumed to live till publication. They are not designed for change and they lack traceability. The models are 'not engineered'







The biggest (software) engineering problem in the world ... ever! Means planning for the management and engineering challenges now. Not modelling, not biology but model management





## **Immediate Implications**

- Intermediating infrastructure
- Configuration and version management
- Fine grain workflow management
- Methodological alignment

#### What we have done:

- A framework for selecting modelling schemes
- A metamodel for systems biology
- A model parameter repository
- A prototype middleware for integrating heterogeneous modelling platforms
- A unified ontology framework for systems biology models
- A new versioning and impact analysis tool for systems biologists

(the first) modular, integrative, scale-crossing, hybrid model of liver glucose homeostasis



- Unlike projects to map genomes there is no clear endpoint for systems biology. Important staging posts:
  - models that provide 'thin' vertical slices across scales are one such
  - the development of models that are approved for drug testing, perhaps in place of animal models, and that satisfy the strict requirements of validity, reliability, transparency and traceability
  - the establishment of global 'collaboratories' in which models can be exchanged, reviewed and analysed
- Finally, when we can dependably diagnose health issues and identify novel treatments using our models, systems biology will have come of age